These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Dose escalation of N,N',N"-triethylenethiophosphoramide combined with pentoxifylline for advanced breast cancer. Shapiro CL; Dezube BJ; Tretyakov O; Wright J; Cap B; Henderson IC; Hayes DF Clin Cancer Res; 1995 Aug; 1(8):791-6. PubMed ID: 9816047 [TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Heideman RL; Cole DE; Balis F; Sato J; Reaman GH; Packer RJ; Singher LJ; Ettinger LJ; Gillespie A; Sam J Cancer Res; 1989 Feb; 49(3):736-41. PubMed ID: 2491958 [TBL] [Abstract][Full Text] [Related]
5. Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites. Cohen BE; Egorin MJ; Kohlhepp EA; Aisner J; Gutierrez PL Cancer Treat Rep; 1986 Jul; 70(7):859-64. PubMed ID: 2424593 [TBL] [Abstract][Full Text] [Related]
6. Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor. O'Dwyer PJ; LaCreta FP; Schilder R; Nash S; McAleer C; Miller LL; Hudes GR; Ozols RF J Clin Oncol; 1992 Aug; 10(8):1352-8. PubMed ID: 1634926 [TBL] [Abstract][Full Text] [Related]
7. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors. Supko JG; Balcerzak SP; Kraut EH Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671 [TBL] [Abstract][Full Text] [Related]
8. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. de Jonge ME; Huitema AD; Holtkamp MJ; van Dam SM; Beijnen JH; Rodenhuis S Cancer Chemother Pharmacol; 2005 Oct; 56(4):370-8. PubMed ID: 15838656 [TBL] [Abstract][Full Text] [Related]
9. A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies. Hidalgo M; Rodriguez G; Kuhn JG; Brown T; Weiss G; MacGovren JP; Von Hoff DD; Rowinsky EK Clin Cancer Res; 1998 Nov; 4(11):2763-70. PubMed ID: 9829740 [TBL] [Abstract][Full Text] [Related]
10. Phase I trial of escalating pentoxifylline dose with constant dose thiotepa. Dezube BJ; Eder JP; Pardee AB Cancer Res; 1990 Nov; 50(21):6806-10. PubMed ID: 2119882 [TBL] [Abstract][Full Text] [Related]
11. Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors. Hara J; Osugi Y; Ohta H; Matsuda Y; Nakanishi K; Takai K; Fujisaki H; Tokimasa S; Fukuzawa M; Okada A; Okada S Bone Marrow Transplant; 1998 Jul; 22(1):7-12. PubMed ID: 9678789 [TBL] [Abstract][Full Text] [Related]
12. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy. de Jonge ME; Huitema AD; Tukker AC; van Dam SM; Rodenhuis S; Beijnen JH Clin Cancer Res; 2005 Jan; 11(1):273-83. PubMed ID: 15671556 [TBL] [Abstract][Full Text] [Related]
13. A search for new metabolites of N,N',N''-triethylenethiophosphoramide. van Maanen MJ; Tijhof IM; Damen JM; Versluis C; van den Bosch JJ; Heck AJ; Rodenhuis S; Beijnen JH Cancer Res; 1999 Sep; 59(18):4720-4. PubMed ID: 10493531 [TBL] [Abstract][Full Text] [Related]
14. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network. Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119 [TBL] [Abstract][Full Text] [Related]
15. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas. Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimen. Ekhart C; Rodenhuis S; Beijnen JH; Huitema AD Ther Drug Monit; 2009 Feb; 31(1):95-103. PubMed ID: 19155964 [TBL] [Abstract][Full Text] [Related]
17. Sensitization of human melanoma cells to the cytotoxic effect of melphalan by the glutathione transferase inhibitor ethacrynic acid. Hansson J; Berhane K; Castro VM; Jungnelius U; Mannervik B; Ringborg U Cancer Res; 1991 Jan; 51(1):94-8. PubMed ID: 1988111 [TBL] [Abstract][Full Text] [Related]
18. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies. Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432 [TBL] [Abstract][Full Text] [Related]
19. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136 [TBL] [Abstract][Full Text] [Related]
20. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Chen TL; Passos-Coelho JL; Noe DA; Kennedy MJ; Black KC; Colvin OM; Grochow LB Cancer Res; 1995 Feb; 55(4):810-6. PubMed ID: 7850794 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]